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Abstract
Ionizing radiation induces modification of the tumor microenvironment such as tumor surrounding region, which is relevant
to treatment outcome after radiotherapy. In this study, the effects of pre-irradiated tumor beds on the growth of
subsequently implanted tumors were investigated as well as underlying mechanism. The experimental model was set up by
irradiating the right thighs of C3H/HeN mice with 5 Gy, followed by the implantation of HCa-I and MIH-2. Both implanted
tumors in the pre-irradiated bed showed accelerated-growth compared to the control. Tumor-infiltrated lymphocyte (TIL)
levels were increased, as well as pro-tumor factors such as IL-6 and transforming growth factor-beta1 (TGF-b1) in the pre-
irradiated group. In particular, the role of pro-tumor cytokine interleukin-17A (IL-17A) was investigated as a possible target
mechanism because IL-6 and TGF-b are key factors in Th17 cells differentiation from naı¨ve T cells. IL-17A expression was
increased not only in tumors, but also in CD4+ T cells isolated from the tumor draining lymph nodes. The effect of IL-17A on
tumor growth was confirmed by treating tumors with IL-17A antibody, which abolished the acceleration of tumor growth.
These results indicate that the upregulation of IL-17A seems to be a key factor for enhancing tumor growth in pre-irradiated
tumor beds.
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Introduction
In cancer radiotherapy (RT), high dose irradiated regions are
always surrounded by areas of graded exposure doses ranging
from medium- to low-doses [1]. Since tumor cells can be
distributed at the microscopic level in a relatively wide area,
circulating tumor cells might be present in surrounding areas that
have received lower doses of irradiation. When tumor recurrence
occurs in these low-dose irradiated areas, the recurrent tumor
exhibits a more aggressive behavior than the primary counterpart
[2]. However, this phenomenon has not been proved in a clinical
setting yet, although the possibility that it could have a clinical
implication has not been excluded. Therefore, surrounding areas
receiving low-doses of irradiation, such as normal tissue in the
vicinity of tumor or pre-irradiated areas, require special attention
to achieve effective cancer control.
Many recent studies have shown radiation effects at lower-than-
ablative doses in normal tissues. Irradiating normal tissue with
low-doses could lead to the accumulation of DNA damage [3].
Chou et al. showed that irradiating endothelial cells with 4 Gy
induced IL-6 expression, which acts through Mcl-1 expression to
protect endothelial cells from irradiation-induced cell death [4]. It
has been reported that irradiation-induced differential changes in
the profiles of cytokines, including IL-6, IL-1a, keratinocyte-
derived chemokine (KC), granulocyte colony-stimulating factor
(G-CSF), and IL-17 in lung tissue irradiated with 12 Gy [5].
Several inflammatory cytokines are considered to be key factors
that lead to tumor recurrence and metastasis in RT, and many
recent studies have reported a role of IL-17 in tumor progression
[6,7].
IL-17, a proinflammatory cytokine that plays a critical role in
the inflammatory response, autoimmune diseases, and cancer
immunity, acts as a potent regulator of tumor growth as well as an
important mediator in inflammatory reactions through the
recruitment of monocytes and neutrophils [8,9]. However, the
role of IL-17 in tumor growth and metastasis is still unclear.
The role of pre-irradiated tumor beds on the growth of
subsequently implanted tumors has been investigated extensively.
Saeki et al. showed that pre-irradiated tumor beds that received
injury induced by a single high-dose to the host vasculature and
connective tissue showed impaired neovascularization in the
implanted tumor [10]. However, high ablative-doses are seldom
given to a substantial area of normal tissue. In current practice in
stereotactic radiosurgery, where very high-dose irradiation is
administered in one fraction, only a very small volume of normal
tissue is included in the radiation field. Therefore, the effect of
irradiating tumor beds with medium- to low-doses on the growth
of subsequently implanted tumors require clinical attention and
mechanism study. In the present study, we investigated the effect
of medium- to low-dose pre-irradiation of tumor beds on the
growth of subsequently implanted tumors. In particular, the role of
the pro-inflammatory cytokine IL-17A was investigated in vitro
and in vivo as a possible factor in the target mechanism.
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Materials and Methods
Reagents
Anti-bodies of TGF-b and ROR-c were purchased from Santa
Cruz Biotechnology (CA). IL-6 and IL-17A anti-bodies were
purchased from abcam (MA). p-stat-3 was purchased from Bio
World (MN). IL-6 ELISA kit and CD4 anti-body were obtained
from BD Bioscience (CA). TGF-b ELISA kit were purchased from
BioLegend (CA). mIL-17A antibody was purchased to IL-17A
neutralization from R&D system (MN). A reverse transcription
system for cDNA synthesis and the primer sets of TGF-b and IL-6
were purchased from Qiagen (Hilden, Germany).
Animal experimental design and X-ray irradiation
Five male C3H/HeN mice, 6 to 7 weeks old (Central Lab,
Japan), were used per each experimental group for this study.
Mice were immobilized in specially designed mice jig and the right
thighs of the mice were irradiated with 5 Gy in a single fraction
using an X-Rad 320 irradiator (Precision X-ray, North Branford,
CT). Mice were treated 69 cm from the radiation source (SSD)
with a dose rate of 150 cGy/min with 300 kVp X-rays, using
12.5 mA and a X-ray beam filter consisting of 2.0 mm Al. On day
1 and 3 after irradiation, HCa-I [11,12] and MIH-2 [13,14]
murine hepatocarcinoma cells (16106 cells) in 100 ml phosphate-
buffered saline (PBS) were injected intramuscularly into irradiated
the site. Tumor volume was calculated as volume = p/6 X ab2,
where a is the long axis and b is the short axis of two orthogonal
diameters. The maximum allowable size of tumors in mice is
20 mm in diameter according to the IACUC (Institutional Animal
Care and Use Committee) guidelines of the Yonsei University
Health System. After experiments, the experimental mice were
sacrificed before reaching the maximum allowable size using
carbon dioxide (CO2).
Tumor infiltrating lymphocytes (TILs) isolation and Flow
cytometry analysis
For the isolation of TILs, tumor were chopped by clipper then
incubated in 1 mg/ml collagenase type IV (Worthington, Lake
wood, NJ) solution containing 0.01 mg/ml DNase I (sigma, CA) at
37uC for 20 min. TILs were isolated by Percoll gradient (sigma,
CA) after washing the dissociated tissues by chilled complete
RPMI medium. Isolated TILs were resuspended in PBS and
stained with the indicated reagents. Cells were then washed twice,
fixed in 2% paraformaldehyde solution, and immediately analyzed
using a FACS Canto flow cytometer (Becton Dickinson, CA).
Analysis of gene expression
Total RNA was isolated from tumor cells using TRIzol reagent
(Invitrogen Corp., Carlsbad, CA). PCR was performed using the
Step One Plus (Applied Biosystems, CA) and a QuantiTect SYBR
Green PCR Kit (Applied Biosystems, Warrington, UK). The
amplification program consisted of 1 cycle of 95uC with a 10 min
hold (hot start), followed by 35 cycles of 95uC with a 20 sec hold,
60uC with a 20 sec hold, and 72uC with a 20 sec hold. After
normalization with GAPDH, the median target level of implanted
tumor only and non-irradiated bed were used as calibrators.
Immunohistochemical and immunofluorescence staining
Tumor samples were fixed in 10% formalin and were
embedded in paraffin, which was cut into 5-mm-thick sections.
For immunohistochemical staining, deparaffinized sections were
blocked with 10% normal horse serum for 1 h and then incubated
with primary antibodies against TGF-b, CD-31 and IL-17A
(1:100). The samples were incubated with biotinylated secondary
antibody (DAKO code K0675; DAKO Corp., Carpinteria, CA)
and peroxidase-labeled streptavidin (DAKO code K0675). Stain-
ing was developed using the 3-3 diaminobenzidine (DAB) substrate
chromogen system (DAKO Corp.).
To immunofluorescence staining, deparaffinized sections were
blocked with 10% normal horse serum for 1 h and then incubated
with primary antibodies against TGF-b and IL-6. And then, the
samples were incubated with Alexa 594-conjugated donkey anti-
rabbit IgG (Invitrogen).
Co-immunofluorescence staining was also performed to assess
co-localization of CD4 and Ror-c. The sections were incubated
overnight with a mixture of anti-CD4 and anti-Ror-c in 4uC
followed by washes with PBS and incubation with a mixture of
Alexa 488-conjugated donkey anti-goat IgG and Alexa 594-
conjugated goat anti-rat IgG (Invitrogen). The reactions were
examined using an immunofluorescence microscope.
Cytokine detection
IL-6 and IL-17A protein were measured in culture supernatants
by enzyme immunometric assays (ELISA). ELISAs were per-
formed using specific mAb pairs for the detection of both IL-6 and
IL-17A. For sandwich ELISAs, purified antimouse IL-6 and IL-
17A antibodies were adsorbed to capture cytokines on 96-well
immunoassay plates. The culture supernatant at the appropriate
dilution was incubated following the addition of biotinylated
antimouse IL-6/IL-17A mAbs. Streptavidin-HRP (BD Pharmin-
gen) was used for detection, followed by the addition of the TMB
substrate reagent set (BD Pharmingen, San Diego, CA).
Th17 cell differentiation from naı¨ve CD4+ T cells
Naive CD4+ T cells were isolated from spleen of C3H/HeN
mice by negative selection using mouse CD4+ T cell isolation kit
(Miltenyi Biotec). Purified-naı¨ve CD4+ T cells were stimulated in
vitro with anti-CD3 (1 mg/ml) anti-CD28 (1 mg/ml) antibodies in
5 Gy irradiated- or no irradiated media. For Th17 polarizing in
vitro, Th17 polarizing factors except TGF-b (anti-IFNc (2 mlg/
ml), anti-IL-4 (2 mlg/ml), rmIL-6 (10 ng/ml) were added to
culture media. These were cultured for 4 days.
IL-17 neutralization in vivo
Approximately 16106 HCa-I and MIH-2 were injected
intramuscularly in the pre-irradiated site day 3 after the
implantation site had been irradiated with 5 Gy. 100 mg a-IL-
17A antibody was treated with intraperitoneally (i.p.) at day 3 and
day 10 after inoculation of tumor cells and with intratumoral (i.t.)
twice a week for 2 weeks after tumor formation reached 8 mm.
IgG2a antibody was administered to control mice using the same
method.
Ethics statement
All procedure of animal research was provided in accordance
with the Laboratory Animals Welfare Act, the Guide for the Care
and Use of Laboratory Animals and the Guidelines and Policies
for Rodent experiment provided by the IACUC in Yonsei
University Health System (Permit Number: 2011-0114). All
animal surgery was performed after euthanasia using CO2, and
all efforts were made to minimize suffering.
Statistical analysis
Data are expressed as means 6 SEM. Comparisons among
multiple groups were performed by factorial analysis of variance
(ANOVA) followed by Scheffe’s test or statistical comparisons
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Figure 1. Tumor Growth and tumor related factors of implanted tumor in non-irradiated or pre-irradiated tumor beds with 5 Gy. (A)
Growth rate of HCa-1 in various dose irradiated tumor beds. 16106 murine hepatocarcinoma cells (HCa-1) were injected intramuscularly in the right
thigh of the mice on day 1 after the implantation site had been irradiated. (n = 5 mice per group) *p,0.05, pre 5 Gy/D1 vs control (ANOVA) (B) Growth
rate of HCa-I and (C) MIH-2 tumors (n = 5 mice per group), (D) expression of CD31 and (E) p-stat3 in implanted tumor. Approximately 16106 murine
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between groups were made by unpaired two-sided t-tests.
Differences of p,0.05 (*) and p,0.01 (**) were considered
significant.
Results
The growth of implanted tumors into low-dose pre-
irradiated the tumor bed was accelerated compared with
non-irradiated the tumor bed
When patients with HCC are treated in single fraction of 20 Gy,
the surrounding regions of the tumor are exposure to graded doses
(Sup Fig. 1). Tumor cells are distributed at the microscopic level in
the surrounding area that has received lower doses of irradiation.
The tumor growth can be affected by low-dose pre-irradiation.
Therefore, to investigate the effect of pre-irradiation on the growth
of subsequently implanted tumors after pre-irradiating the tumor
bed, experimental models were developed by irradiating the right
thighs of C3H/HeN mice with various doses followed by
implantation of syngeneic tumor cells of murine hepatocarcinoma
(HCa-I). As shown in Fig 1, tumor growth was accelerated in areas
that received below 5 Gy, while the growth of the implanted tumor
into the high-dose irradiated tumor bed (more than 7 Gy) was slow
(Fig 1A). Therefore, we investigated the effect of the low-dose pre-
irradiating tumor bed and the change of tumor microenvironment
by pre-irradiation using 5 Gy and syngeneic murine hepatocar-
cinomas (HCa-I and MIH-2) in this study. HCa-I is a rapidly
growing tumor that is resistant to radiation, while MIH-2 is a slow-
growing tumor that is sensitive to radiation in relative comparison
to HCa-I. The growth of both tumors was faster in the pre-
irradiated bed than that in the non-irradiated bed (Figure 1, B and
C). In addition, expression of pro-tumor factors, such as platelet
endothelial cell adhesion molecule (PECAM-1, CD 31) and p-
stat3, increased in both tumors in the pre-irradiated beds
(Figure 1D and E).
Pre-irradiation on tumor bed increased TGF-b in
implanted tumors and the tumor bed
TGF-b has multiple tumor-promoting effects and it can be
induced by irradiation [15]; therefore, its expression was measured
in the implanted tumors. TGF-b expression and its mRNA levels
were higher at the tumor edges as well as in both the tumors
implanted in the pre-irradiated beds than those in the control were
(Figure 2A, B and Figure S2). TGF-b expression and mRNA level
in the irradiated skin and muscles of the mice on day 3 of
irradiating their thighs with 5 Gy was investigated because skin
and muscles acted as tumor beds. It was highly expressed in
vascular endothelial cells as well as in fibroblasts of dermis
(Figures 2C and D). Thus, irradiation can induce TGF-b
production in a tumor and its microenvironment, which includes
the stroma and vascular endothelial cells.
Pre-irradiation on tumor bed increased TIL and IL-6 levels
in implanted tumors
IL-6 is believed to have a pro-tumor effect as well as an
inflammatory effect [16]. It is secreted by immune cells and some
non-immune cells such as smooth muscle cells and fibroblasts [17].
Therefore, we investigated TIL and IL-6 production in this study.
TIL increased in both tumors implanted into the pre-irradiated
beds compared to the control (Figure 3A and B). Similarly, IL-6
expression also increased (Figure 3C). Immunofluorescence stain-
ing was performed to check IL-6 levels of pre-irradiated tumor
beds (Figure D). A 5 Gy-irradiation led to increased IL-6 levels in
the tumor bed and infiltration of immune cells (Figures 3D, E, F,
and G).
Pre-irradiation on tumor bed increased IL-6 levels in the
tumor-draining lymph node
We next set out to assess whether pre-irradiation of tumor beds
can influence IL-6 levels in tumor-draining lymph nodes, as the
lymph nodes, among lymphoid tissues, show the greatest
involvement in mediating inflammatory responses. As shown in
Figure 4, IL-6 levels were slightly increased in the tumor-draining
lymph nodes of the pre-irradiated group, compared to control.
These results potentially suggest that the enhancement of tumor
growth in pre-irradiated tumor beds might be influenced by
factors other than IL-6.
Pre-irradiation on tumor bed showed increased IL-17A in
tumor-draining lymph node
Our results showed that IL-6 and TGF-b expressions increased
in tumors implanted in pre-irradiated beds. TGF-b and IL-6 are
required to induce Th17 differentiation from naive T cells [18].
IL-17A, in particular, plays an important role in cancer
development and in inflammatory responses [6]; therefore, we
investigated IL-17A and Th17 cell populations. To investigate IL-
17A and Th17 cells in tumors, both tumor tissues were stained
with IL-17A antibody and co-stained with CD4 and Ror-ct
antibodies because Th17 cells are CD4- and Ror-ct-positive. We
found an increase in IL-17A in both tumors implanted in the pre-
irradiated beds, compared to controls (Figure 5A). Th17 cells also
increased in number in both tumors implanted in the pre-
irradiated beds, compared to controls (Figure 5B). To evaluate IL-
17A levels in T cells, CD4+ T cells were isolated from tumor-
draining lymph nodes in mice and were cultured for 4 days in the
presence of a-CD3 and a-CD28. IL-17A mRNA levels and
secreted-IL-17A into the media from CD4+ T cells increased in
the pre-irradiated group, compared to the control group
(Figure 5C and D). These data show that enhanced-tumor growth
is closely correlated with IL-17A in pre-irradiated tumor beds.
Th17 cell differentiation was enhanced by irradiation in
vitro
Next, to determine how irradiation to the tumor beds could
induce Th17 cells, we examined Th17 cell differentiation by
irradiation in vitro. First, we isolated dermal fibroblasts from mice
and these were irradiated with 5 Gy. An irradiation of 5 Gy
increased IL-6 and TGF-b levels in dermal fibroblasts (Figure S3).
Isolated-naı¨ve CD4+ T cells from spleen were cultured for 4 days
in conditioned medium derived from irradiated-dermal fibroblasts
or no irradiated-dermal fibroblasts. For Th17 polarizing in vitro,
Th17 polarizing factors except TGF-b were added to culture
media (Anti-IFN-c (2 mlg/ml), Anti-IL-4 (2 mlg/ml) and small
amount rmIL-6 (10 ng/ml) than commonly used rmIL-6 for Th17
polarization in vitro. As shown Figure 5E, the differentiation of
naı¨ve T cells towards Th17 cells was enhanced in the conditioned
medium derived from irradiated fibroblasts.
hepatocarcinoma cells (HCa-1 and MIH-2) were injected intramuscularly in the right thigh of the mice on day 1 and 3 after the implantation site had
been irradiated. Error bars denote 6 SEM. *p,0.05, pre 5Gy/D3 vs control (ANOVA). The tumors were resected for histologic examination when the
tumor volume reached 800 to 1200 mm3 and CD31 and p-stat3 were stained.
doi:10.1371/journal.pone.0106423.g001
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Figure 2. TGF-b expression. (A) TGF-b expression and (B) mRNA level in both tumors implanted into irradiated tumor beds or non-irradiated tumor
beds at day 3 after irradiation. (C) TGF-b expression and (D) TGF-b mRNA level of tumor beds with or without 5 Gy-irradiation. p,0.05 (*) and p,0.01
(**) (t-test).
doi:10.1371/journal.pone.0106423.g002
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Figure 3. TIL frequency and IL-6 expression in implanted tumors and irradiated beds. TILs were isolated from the tumor and stained with
CD4+ and CD8+ antibodies which was analyzed by FACS. (A) frequency of infiltrated CD4+ and CD8+ T cells and (B) Summary of TIL frequency in HCa-I
and MIH-2 tumors. (C) IL-6 expression in both tumors. Irradiated beds were analyzed at day 3 after 5 Gy irradiation. (D) Representative
Accelerated Tumor Growth by IL-17A in Pre-Irradiated Beds
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Tumor progression was inhibited by IL-17A neutralization
in implanted tumors in pre-irradiated beds
When tumor cells were inoculated into irradiated tumor beds,
the tumor growth rate and IL-17A expression drastically were
increased relative to the controls. In addition, recombinant hIL-
17A (rhIL-17A) treatment increased the proliferation of human
hepatocellular carcinoma, HepG2 cells in vitro (Figure S4).
Therefore, we further examined whether IL-17A neutralization
can rescue accelerated tumor growth in pre-irradiated beds. As
shown in figure 6A and C, neutralization of IL-17A suppressed the
accelerated tumor growth in pre-irradiated tumor beds. Moreover,
IL-17A decreased following IL-17A neutralization in both tumors
implanted in the pre-irradiated beds (Figure 6B and D). There-
fore, irradiating tumor beds might enhance the growth of
subsequently implanted tumors via IL-17A.
Discussion
The effect of a high, ablative-radiation dose to the tumor bed on
the growth of subsequently an implanted tumor has been
extensively investigated, and is known as the tumor bed effect
(TBE). The TBE was first described by Frankl and Kimball and
was named the TBE by Senstrom [19]. A high-dose of irradiation
to the tumor bed induced injury to the host vasculature and
connective tissue, resulting in impaired neovascularization in the
implanted tumor [10]. It has been reported that implanted tumor
growth was inhibited in high-dose (20 Gy) pre-irradiated beds,
while tumor metastasis increased through increased hypoxia-
associated factors [20]. Although the nature of TBE has long been
recognized, its mechanism is still uncertain.
In this study, we investigated the effect of low-dose pre-
irradiation (5 Gy) on the tumor bed where tumor cells were
subsequently implanted. In current practice hypofractionated RT,
a low-dose region usually present around the region exposed to a
high, lethal dose. Tumor of areas receiving low-doses of irradiation
may be affected to tumor growth by pre-irradiation. Fig 1A
showed that tumor growth was accelerated in areas that received
below 5 Gy. More frequently, 5 Gy-fraction hypofractionated RT
is used in a clinical setting [21,22], thus 5 Gy was used in this
study.
The growth of implanted tumors in 5 Gy pre-irradiated beds
was accelerated by IL-17A, compared to the controls. In HCa-I,
tumor growth in the pre-irradiated beds was faster in the pre-5
Gy/D1 and D3 groups than in the control group, and was
correlated with IL-17A production. However, MIH-2 showed
faster growth only in the pre-5 Gy/D3 group, and there was only a
slight difference in tumor growth between the control and pre-5
Gy/D1 groups. This might be attributable to a decrease in the
potency of IL-17A in the pre-5 Gy/D1 group of MIH-2 than that
in HCa-I.
In this study, tumor growth was suppressed by IL-17A
neutralization; however, growth was still slightly faster than that
in the non-irradiated control. This suggests that other factors in
addition to IL-17A might promote tumor growth in pre-irradiated
beds.
Several studies have shown that IL-6 inhibits radiation-induced
apoptosis and enhances cell survival via stat3 activation [23,24].
Fujikawa et al. reported that the IL-6-induced inflammatory
response can suppress immune-mediated anti-tumor effects [25].
In this study, IL-6 level in the tumor-draining lymph nodes of
irradiated group was slightly induced compared to control. Our
results also showed that a 5 Gy irradiation increased TGF-b.
TGF-b suppresses tumor growth during tumor initiation, but it
may in fact promote tumor progression and cancer cell
invasiveness in later stages [26]. Accordingly, irradiation-induced
IL-6 and TGF-b could act separately as a pro-tumor factor as well
as accelerated tumor growth through the induction of IL-17A in
this study. However, IL-17A was significantly increased in
immunofluorescence staining for IL-6, (E) western blotting for IL-6, (F) IL-6 mRNA level and (G) histology in 5 Gy irradiated beds. p,0.05 (*) and p,
0.01 (**) (t-test).
doi:10.1371/journal.pone.0106423.g003
Figure 4. IL-6 expression in the tumor-draining lymph node of tumor bearing mice. (A and B) IL-6 expression in the tumor draining lymph
node from HCa-I and MIH-2 bearing mice. p,0.05 (*) and p,0.01 (**) (t-test).
doi:10.1371/journal.pone.0106423.g004
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Figure 6. The effect of treatment with a-IL-17A neutralizing antibody on tumor growth. (A and C) Growth delay and (B and D) IL-17A
expression of HCa-I and MIH-2 tumors implanted in 5 Gy irradiated beds or non-irradiated beds by a-IL-17A treatment, respectively (n = 5 mice per
group). Error bars denote 6 SEM. *p,0.05, pre 5 Gy/D3/a-IL-17 vs pre 5 Gy/D3/IgG2a (ANOVA).
doi:10.1371/journal.pone.0106423.g006
Figure 5. IL-17A expression in the tumor-draining lymph node of tumor bearing mice and Th17 differentiation by irradiation in
vitro. (A) Expressions of IL-17A and (B) Th17 cells (CD4+ and Ror-ct double positive cells) in both tumors. (C) IL-17A mRNA level and protein
expression in the tumor draining lymph node of HCa-I bearing mice. (D) IL-17A mRNA level and protein expression in the tumor-draining lymph node
of MIH-2 bearing mice. (E) Th17 differentiation by irradiation in vitro. Murine fibroblasts were cultured for 3 days after irradiating cells with 5 Gy. Naı¨ve
CD4+ T cells were isolated from the spleen, which were then cultured for 4 days in conditioned medium derived from irradiated fibroblasts or non-
irradiated fibroblasts. Secreted IL-17A from Th17 cells was analyzed by ELISA. IL-17A mRNA level was evaluated using quantitative real time PCR. rmIL-
6 (10 ng/ml), a-IFN-c (2 mg/ml), and a-IL-4 (2 mg/ml) were added to the culture media. p,0.05 (*) and p,0.01 (**) (t-test).
doi:10.1371/journal.pone.0106423.g005
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draining lymph nodes of the irradiated group, compared to IL-6
and its expression exhibited a correlation with enhanced tumor
growth. Therefore, IL-17A might be a major factor for enhancing
tumor growth in low-dose pre-irradiated tumor beds.
IL-17A is mainly secreted by Th17 cells, which may influence
cancer progression. IL-17B, IL-17C, IL-17D, IL-17E/IL-25, and
IL-17F have all been identified in humans and cloned [27].
Among these, IL-17A has been detected in several human cancers.
IL-17A promotes hepatocellular carcinoma (HCC) metastasis via
matrix metalloproteinase (MMP) 2 and 9 [28]. In contrast,
another study showed that endogenous IL-17 reduces tumor
growth and metastasis [29]. Although, the role of IL-17 in cancer
has not been fully studied, the clinical evidence of IL-17A and
Th17 cells as pro-tumor factors in HCC have recently been
reported. It has shown that increased IL-17 production in T cells
from tumors or blood of HCC patients is correlated with both
micro-vessel density and poor prognosis, suggesting the potential
role of IL-17 as a pro-tumor factor [30,31]. It was also reported
that the inhibition of monocytes/macrophage-derived inflamma-
tion in hepatoma-bearing mice suppresses tumor-infiltrating Th17
cell numbers, resulting in a reduction of tumor growth [32]. Thus,
IL-17A seems to be a specific target in HCC. Indeed, this study
demonstrated that low-dose pre-irradiation of tumor beds
subsequently enhanced implanted-hepatoma growth in vivo,
which was suppressed by IL-17A neutralization. Therefore, we
suggest that IL-17A may be used as a novel therapeutic approach
to improve the outcome of patients with HCC receiving RT
through preventing recurrence in low-dose normal liver. However,
further studies are needed to determine whether blocking IL-17A
helps in preventing recurrence of both the primary irradiated
tumor and recurrence in low-dose normal livers.
In conclusion, the results of our study suggest that low-dose
irradiation of tumor beds can induce IL-17A production via IL-6
and TGF-b production, and promote the growth of subsequently
implanted tumors. IL-17A seems to be a key factor for enhancing
tumor growth in pre-irradiated tumor beds.
Supporting Information
Figure S1 Iso dose lines of the patient with Hepatocellular
carcinoma receiving 20 Gy single fractionation RT.
(TIF)
Figure S2 Expression of TGF-b by pre-irradiation of tumor bed
in tumor border and tumor. Approximately 16106 HCa-1 cells
were injected intramuscularly in the right thigh of the mice on day
3 after the implantation site had been irradiated with 5 Gy.
(TIF)
Figure S3 Murine fibroblasts were isolated from mice skin that
were irradiated with 5 Gy. (A) TGF-b and (B) IL-6 expression was
assessed by ELISA in irradiated-murine fibroblasts cultured media
3 day after irradiation, respectively. Data are representative of
three independent experiments.
(TIF)
Figure S4 Proliferation of HepG2 cells by rhIL-17. HepG2 cells
were treated with rhIL-17A of concentration from 0 to 100 ng/ml.
Data are representative of three independent experiments.
(TIF)
Author Contributions
Conceived and designed the experiments: EJL JS. Performed the
experiments: EJL HJP WWK. Analyzed the data: EJL JS IJL YGS SJH.
Contributed reagents/materials/analysis tools: JS SJH. Wrote the paper:
EJL JS.
References
1. Purdy JA (2008) Dose to normal tissues outside the radiation therapy patient’s
treated volume: a review of different radiation therapy techniques. Health
physics 95: 666–676.
2. Kuonen F, Secondini C, Ruegg C (2012) Molecular pathways: emerging
pathways mediating growth, invasion, and metastasis of tumors progressing in an
irradiated microenvironment. Clinical cancer research 18: 5196–5202.
3. Pogribny I, Koturbash I, Tryndyak V, Hudson D, Stevenson SM, et al. (2005)
Fractionated low-dose radiation exposure leads to accumulation of DNA
damage and profound alterations in DNA and histone methylation in the
murine thymus. Molecular cancer research 3: 553–561.
4. Chou C, Chen S, Cheng JC (2009) Radiation-induced interleukin-6 expression
through MAPK/p38/NF-kappaB signaling pathway and the resultant anti-
apoptotic effect on endothelial cells through Mcl-1 expression with sIL6-Ralpha.
International journal of radiation oncology, biology, physics 75: 1553–1561.
5. Ao X, Zhao L, Davis M, Lubman D, Lawrence T, et al. (2009) Radiation
produces differential changes in cytokine profiles in radiation lung fibrosis
sensitive and resistant mice. J Hematol Oncol 2:6.
6. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, et al. (2003)
Interleukin-17 promotes angiogenesis and tumor growth. Blood 101: 2620–
2627.
7. Zou W, NP R (2010) Th17 cells in tumour immunity and immunotherapy.
Nature Review 10: 248–256.
8. Park H, Li Z, Yang XO, Chang SH, Nurieva R, et al. (2005) A distinct lineage of
CD4 T cells regulates tissue inflammation by producing interleukin 17. Nature
Immunology 6: 1133–1141.
9. Van den Berg WB, Miossec P (2009) IL-17 as a future therapeutic target for
rheumatoid arthritis. Nature Reviews Rheumatology 5: 549–553.
10. Saeki Y, Shimazaki S, Urano M (1971) Radiation effect on the vascularization of
a C3H mouse mammary carcinoma. Microangiographic studies of the tumor in
preirradiated tissue and of the recurrent tumor. Radiology 101: 175–180.
11. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, et al. (1996)
Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel.
Journal of the National Cancer Institute 88: 1308–1314.
12. Kim W, Seong J, Oh HJ, Koom WS, Choi K, et al. (2011) A novel combination
treatment of armed oncolytic adenovirus expressing IL-12 and GM-CSF with
radiotherapy in murine hepatocarcinoma. journal of radiation research 52: 646–
654.
13. Irie M, Homma S, Komita H, Zeniya M, Kufe D, et al. (2004) Inhibition of
spontaneous development of liver tumors by inoculation with dendritic cells
loaded with hepatocellular carcinoma cells in C3H/HeNCRJ mice. Interna-
tional journal of cancer 111: 238–245.
14. Park HJ, Kusnadi A, Lee EJ, Kim WW, Cho BC, et al. (2012) Tumor-infiltrating
regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors.
Cellular immunology 278: 76–83.
15. Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, et al. (1999) Role of
transforming growth factor-beta 1 in invasion and metastasis in gastric
carcinoma. Journal of clinical oncology 17: 607–614.
16. Hodge DR, Hurt EM, Farrar WL (2005) The role of IL-6 and STAT3 in
inflammation and cancer. European journal of cancer 41: 2502–2512.
17. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, et al. (1997) Role
of IL-6 and its soluble receptor in induction of chemokines and leukocyte
recruitment. Immunity 6: 315–325.
18. Morishima N, Mizoguchi I, Takeda K, Mizuguchi J, Yoshimoto T (2009) TGF-
beta is necessary for induction of IL-23R and Th17 differentiation by IL-6 and
IL-23. Biochemical and biophysical research communications 386: 105–110.
19. Stenstrom KW, Vermund H, Mosser DG, Marvin JF (1955) Effects of roentgen
irradiation on the tumor bed. I. The inhibiting action of local pretransplantation
roentgen irradiation (1500 r alpha) on the growth of mouse mammary
carcinoma. Radiation Research 2: 180–191.
20. Rofstad EK, Mathiesen B, Henriksen K, Kindem K, Galappathi K (2005) The
tumor bed effect: increased metastatic dissemination from hypoxia-induced up-
regulation of metastasis-promoting gene products. Cancer research 65: 2387–
2396.
21. Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, et al. (2012)
Hypofractionated image-guided radiation therapy for patients with limited
volume metastatic non-small cell lung cancer. Journal of thoracic oncology 7:
376–381.
22. Bae SH, Park HC, Lim DH, Gwak GY, Choi MS, et al. (2012) Salvage
treatment with hypofractionated radiotherapy in patients with recurrent small
hepatocellular carcinoma. International journal of radiation oncology, biology,
physics 82: e603–e607.
23. Horiguchi A, Oya M, Marumo K, Murai M (2002) STAT3, but not ERKs,
mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P.
Kidney international 61: 926–938.
Accelerated Tumor Growth by IL-17A in Pre-Irradiated Beds
PLOS ONE | www.plosone.org 10 September 2014 | Volume 9 | Issue 9 | e106423
24. Miyamoto Y, Hosotani R, Doi R, Wada M, Ida J, et al. (2001) Interleukin-6
inhibits radiation induced apoptosis in pancreatic cancer cells. Anticancer
research 21: 2449–2456.
25. Fujikawa K, Matsui Y, Miura K, Kobayashi T, Oka H, et al. (2000) Serum
immunosuppressive acidic protein and natural killer cell activity in patients with
metastatic renal cell carcinoma before and after nephrectomy. The Journal of
urology 164: 673–675.
26. Basanta D, Strand DW, Lukner RB, Franco OE, Cliffel DE, et al. (2009) The
role of transforming growth factor-beta-mediated tumor-stroma interactions in
prostate cancer progression: an integrative approach. Cancer research 69: 7111–
7120.
27. Moseley TA, Haudenschild DR, Rose L, Reddi AH (2003) Interleukin-17 family
and IL-17 receptors. Cytokine & growth factor reviews 14: 155–174.
28. Li J, Lau GK, Chen L, Dong S, Lan H, et al. (2011) Interleukin 17A promotes
hepatocellular carcinoma metastasis via NF-kB induced matrix metalloprotei-
nases 2 and 9 expression. PLoS ONE 6: e21816–e21816.
29. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W (2009) Endogenous IL-17
contributes to reduced tumor growth and metastasis. Blood 114: 357–359.
30. Zhang J, Yan J, Xu J, Pang X, Chen M, et al. (2009) Increased intratumoral IL-
17-producing cells correlate with poor survival in hepatocellular carcinoma
patients. Journal of hepatology 50: 980–989.
31. Wang W, Wang Z, Liu Y, Qin Y, Shen Q (2010) Increased level of Th17 cells in
peripheral blood correlates with the development of hepatocellular carcinoma.
J chinese Oncol 32: 757–761.
32. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, et al. (2010) Activated
Monocytes in Peritumoral Stroma of Hepatocellular Carcinoma Promote
Expansion of Memory T Helper 17 Cells. Hepatology 51: 154–164.
Accelerated Tumor Growth by IL-17A in Pre-Irradiated Beds
PLOS ONE | www.plosone.org 11 September 2014 | Volume 9 | Issue 9 | e106423
